Write notes on liquid based cytology from berek and novak 10 mark answer with proper flowchart,diagrams,easy explanation for final main m.s exam
Reading File
Now let me search the medical library for LBC content from Berek & Novak, and simultaneously search the web and PubMed.
Finding Sources
Finding Sources
Searching the Web
liquid based cytology cervical cancer screening Berek Novak gynecology LBC vs conventional pap smear
Now let me search specifically for Berek & Novak content and get more detailed LBC information from the library:
Finding Sources
Finding Sources
Finding Sources
Excellent! Found Berek & Novak content. Let me read that section and get more content from the book:
Reading File
Finding Sources
Let me read the specific LBC section in Berek & Novak and also look for more content:
Reading File
Finding Sources
Excellent! I have the core content from Berek & Novak. Let me read a bit more of this section for complete coverage:
Reading File
Finding Sources
I now have comprehensive content from Berek & Novak. Let me also get the Bethesda classification content and read the Histology textbook's clinical correlation section:
Reading File
Finding Sources
I now have comprehensive content from Berek & Novak and supplementary sources. Let me compile the comprehensive exam notes with flowcharts and diagrams as ASCII/text-based visual aids.
Liquid-Based Cytology (LBC)
Source: Berek & Novak's Gynecology | 10-Mark MS Final Exam Answer
DEFINITION
Liquid-Based Cytology (LBC) is a thin-layer (monolayer) slide preparation technology introduced as an improved alternative to the conventional Papanicolaou (Pap) smear for cervical cancer screening. Instead of directly smearing cervical cells onto a glass slide, cells are rinsed into a vial of liquid alcohol-based preservative and then processed in the laboratory to produce a uniform, thin layer of cells on a slide.
Berek & Novak: "The ubiquitous use of liquid-based medium to collect the cytologic sample and preserve the collected cervical cells significantly decreased specimen sampling and preparation errors."
HISTORICAL BACKGROUND
| Era | Development |
|---|---|
| 1943 | Papanicolaou introduced conventional Pap smear |
| 1950-2000 | Cervical cancer incidence reduced by 79%, mortality by 70% |
| Late 1990s | LBC introduced (ThinPrep FDA-approved 1996) |
| 2000s | LBC becomes standard in USA; UK NHS adopted LBC nationally |
| Present | HPV co-testing + LBC is current gold standard |
WHY WAS LBC NEEDED? (Limitations of Conventional Pap Smear)
The sensitivity of conventional cytology for detecting CIN 2/3 was only 47-62% with a false-negative rate of 49% (Berek & Novak).
PROBLEMS WITH CONVENTIONAL PAP SMEAR
┌─────────────────────────────────────────────────────┐
│ 1. SAMPLING ERRORS │
│ • Only 10-20% cells transferred to slide │
│ • Small lesions may not exfoliate │
│ │
│ 2. PREPARATION ERRORS │
│ • Air-drying artifact │
│ • Slide too thick │
│ • Obscuring blood, mucus, discharge │
│ │
│ 3. INTERPRETIVE ERRORS │
│ • False-negative rate ~49% │
│ • Observer variability │
└─────────────────────────────────────────────────────┘
↓ LBC SOLVES ALL THREE ↓
STEP-BY-STEP TECHNIQUE (FLOWCHART)
╔══════════════════════════════════════════════════════════╗
║ LIQUID-BASED CYTOLOGY - HOW IT WORKS ║
╠══════════════════════════════════════════════════════════╣
║ ║
║ STEP 1: SPECIMEN COLLECTION ║
║ ┌────────────────────────────────────┐ ║
║ │ Endocervical brush + plastic │ ║
║ │ spatula OR plastic broom device │ ║
║ │ (samples transformation zone) │ ║
║ └────────────────┬───────────────────┘ ║
║ ↓ ║
║ STEP 2: RINSING INTO VIAL ║
║ ┌────────────────────────────────────┐ ║
║ │ Device RINSED/SWIRLED in vial │ ║
║ │ containing liquid alcohol-based │ ║
║ │ preservative (NOT smeared) │ ║
║ │ 80-90% cells transferred │ ║
║ │ (vs. 10-20% in conventional Pap) │ ║
║ └────────────────┬───────────────────┘ ║
║ ↓ ║
║ STEP 3: LABORATORY PROCESSING ║
║ ┌────────────────────────────────────┐ ║
║ │ Liquid passed through FILTER │ ║
║ │ → Traps larger epithelial cells │ ║
║ │ → Separates small blood cells, │ ║
║ │ inflammatory cells, debris │ ║
║ └────────────────┬───────────────────┘ ║
║ ↓ ║
║ STEP 4: SLIDE PREPARATION ║
║ ┌────────────────────────────────────┐ ║
║ │ Uniform THIN MONOLAYER deposited │ ║
║ │ onto glass slide │ ║
║ │ • Clean background │ ║
║ │ • Cells properly preserved │ ║
║ │ • Easy microscopic interpretation │ ║
║ └────────────────┬───────────────────┘ ║
║ ↓ ║
║ STEP 5: REPORTING (Bethesda System) ║
║ ┌────────────────────────────────────┐ ║
║ │ NILM → ASCUS → LSIL → HSIL │ ║
║ │ + Reflex HPV testing possible │ ║
║ └────────────────────────────────────┘ ║
╚══════════════════════════════════════════════════════════╝
TWO FDA-APPROVED COMMERCIAL SYSTEMS
┌──────────────────────────────────────────────────────────┐
│ LBC COMMERCIAL SYSTEMS │
├─────────────────────┬────────────────────────────────────┤
│ ThinPrep® │ SurePath® │
├─────────────────────┼────────────────────────────────────┤
│ Hologic Inc. │ BD Diagnostics │
│ Membrane filter │ Density gradient centrifugation │
│ technique │ technique │
│ FDA approved 1996 │ FDA approved 1999 │
│ Most widely used │ Smaller circle of cells │
│ in USA │ Longer preservation time │
│ Specimen in │ Specimen preserved up to │
│ CytoLyt solution │ 4 weeks │
└─────────────────────┴────────────────────────────────────┘
DIAGRAM: LBC vs CONVENTIONAL PAP SMEAR (Side-by-Side)
CONVENTIONAL PAP SMEAR LIQUID-BASED CYTOLOGY
Cervix → Smear on slide Cervix → Rinse in vial
↓ ↓
Air dry + Fix Lab processing (filter/centrifuge)
↓ ↓
THICK uneven smear THIN uniform monolayer
↓ ↓
Debris/blood obscures Clean clear slide
↓ ↓
10-20% cells transferred 80-90% cells transferred
↓ ↓
Sensitivity: 47-62% Sensitivity: ~81%
Unsatisfactory rate: HIGH Unsatisfactory rate: reduced 70-90%
Reflex HPV: NOT possible Reflex HPV: POSSIBLE from same vial
ADVANTAGES OF LBC (Berek & Novak)
| # | Advantage | Mechanism |
|---|---|---|
| 1 | Reduced unsatisfactory samples | 70-90% reduction; clean background, no debris |
| 2 | Higher cell yield | 80-90% cells transferred vs. 10-20% |
| 3 | Eliminates air drying | Immediate fixation in liquid preservative |
| 4 | No obscuring material | Blood, mucus, inflammation filtered out |
| 5 | Reflex HPV testing | Same vial used for HPV DNA testing (ASCUS triage) |
| 6 | Reduced false-negative rate | Sensitivity improved from ~71% to ~81% |
| 7 | Automated screening | Computer-assisted reading possible |
| 8 | Residual material | Can test for gonorrhea, chlamydia from same vial |
| 9 | Longer preservation | Specimen stable for days to weeks |
| 10 | Uniform cell layer | Easier, faster cytotechnologist review |
DISADVANTAGES OF LBC
┌──────────────────────────────────────────────────────┐
│ DISADVANTAGES OF LBC │
├──────────────────────────────────────────────────────┤
│ • MORE EXPENSIVE than conventional Pap smear │
│ • Cells may ROUND UP → appear smaller │
│ • Nuclei appear more vesicular/delicate │
│ • FEWER LANDMARKS on slide to guide screening │
│ • More time-consuming per unit area to review │
│ • Requires SPECIAL EQUIPMENT in laboratory │
│ • Loss of 3D architecture compared to histology │
│ • Background organisms (Trichomonas) may be harder │
│ to identify │
└──────────────────────────────────────────────────────┘
BETHESDA REPORTING SYSTEM (Used for LBC Results)
┌─────────────────────────────────────────────────────────────┐
│ THE BETHESDA SYSTEM (2014) │
├─────────────────────────────────────────────────────────────┤
│ │
│ NILM ─── Negative for Intraepithelial Lesion/Malignancy │
│ (Normal + infections + non-neoplastic reactive changes) │
│ │
│ OTHER ── Benign endometrial cells in woman ≥45 yrs │
│ │
│ EPITHELIAL CELL ABNORMALITIES: │
│ │
│ SQUAMOUS: │
│ ┌─ ASC-US (Atypical Squamous Cells - Undetermined Sig.) │
│ ├─ ASC-H (Atypical Squamous Cells - cannot exclude HSIL)│
│ ├─ LSIL (Low Grade Squamous Intraepithelial Lesion) │
│ │ = HPV + CIN 1 │
│ ├─ HSIL (High Grade Squamous Intraepithelial Lesion) │
│ │ = CIN 2 + CIN 3 │
│ └─ Squamous Cell Carcinoma │
│ │
│ GLANDULAR: │
│ ├─ AGC (Atypical Glandular Cells) │
│ ├─ AIS (Adenocarcinoma in Situ) │
│ └─ Adenocarcinoma │
└─────────────────────────────────────────────────────────────┘
MANAGEMENT FLOWCHART AFTER LBC RESULT
LBC RESULT
│
┌─────────────┼─────────────┐
↓ ↓ ↓
NILM ASC-US LSIL / HSIL
│ │ │
↓ ↓ ↓
Routine Reflex HPV Colposcopy
Screening Testing + Biopsy
│ │
┌───────┴───────┐ ↓
↓ ↓ Confirm
HPV -ve HPV +ve CIN grade
│ │
↓ ↓
Return to Colposcopy
routine + Biopsy
screening
SCREENING GUIDELINES (Berek & Novak / ACOG)
| Age Group | Recommendation |
|---|---|
| < 21 years | No screening (regardless of sexual debut) |
| 21-29 years | LBC or conventional cytology every 2 years |
| 30-65 years | LBC every 3 years OR LBC + HPV co-test every 5 years |
| > 65 years | Discontinue if 3 consecutive negative results |
| Post-hysterectomy (benign) | Discontinue screening |
| HIV+, Immunocompromised | Twice in year 1, then annually |
| CIN 2+ history | Annually for 20 years |
LBC + HPV CO-TESTING (Current Best Practice)
┌──────────────────────────────────────────────────────┐
│ CO-TESTING STRATEGY (Age ≥30) │
│ │
│ LBC Cytology + HPV DNA Testing (same vial) │
│ │ │
│ ┌────────────┴────────────┐ │
│ ↓ ↓ │
│ Cytology -ve Cytology +ve │
│ HPV -ve OR HPV +ve │
│ │ │ │
│ ↓ ↓ │
│ Screen every 5 yrs Follow guidelines │
│ (very low risk) (colposcopy, etc.) │
└──────────────────────────────────────────────────────┘
High-risk HPV types detected: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
AUTOMATED SCREENING (Adjunct to LBC)
A second FDA-approved technology is the automated image-guided slide screening system:
- Uses automated microscope + digital camera
- Computer algorithms scan every field of view
- Ranks slides by probability of abnormality
- Reduced false-negative rate by 32% (Berek & Novak)
- Cytotechnologist reviews only selected high-risk slides
- Increases throughput and consistency
MICROSOPIC FEATURES OF LBC (What the Pathologist Sees)
NORMAL LBC SLIDE:
┌──────────────────────────────────────┐
│ • Thin, uniform layer of cells │
│ • Clean background (no debris) │
│ • Superficial & intermediate cells │
│ • Small pyknotic nuclei │
│ • Abundant cytoplasm │
│ • No obscuring blood/mucus │
└──────────────────────────────────────┘
ABNORMAL LBC SLIDE (HSIL):
┌──────────────────────────────────────┐
│ • Large cells with enlarged nuclei │
│ • High nuclear:cytoplasmic ratio │
│ • Nuclear hyperchromasia │
│ • Irregular nuclear membrane │
│ • Koilocytes (in LSIL/HPV) │
│ = perinuclear halo + nuclear │
│ hyperchromasia │
└──────────────────────────────────────┘
HIGH-YIELD SUMMARY TABLE (For Quick Revision)
| Parameter | Conventional Pap | LBC |
|---|---|---|
| Cell transfer | 10-20% | 80-90% |
| Sensitivity for CIN 2/3 | 47-62% | ~81% |
| False-negative rate | ~49% | Significantly reduced |
| Unsatisfactory samples | Higher | Reduced 70-90% |
| Air-drying artifact | Common | Eliminated |
| Reflex HPV testing | Not possible | Possible (same vial) |
| Cost | Lower | Higher |
| STI testing (GC/Chlamydia) | No | Yes (same vial) |
| Automated reading | Limited | Yes |
| Background clarity | Often obscured | Clean |
| FDA approved systems | N/A | ThinPrep (1996), SurePath (1999) |
EXAM MEMORY AID
LBC - Remember "FILTER"
┌─────────────────────────────────────────────────┐
│ F - Fixation immediate (no air drying) │
│ I - Increased cell yield (80-90%) │
│ L - Less unsatisfactory specimens (↓70-90%) │
│ T - ThinPrep / SurePath (two main systems) │
│ E - Extra tests possible (HPV, GC, Chlamydia) │
│ R - Reflex HPV testing in ASC-US │
└─────────────────────────────────────────────────┘
10-MARK ANSWER STRUCTURE (MS Final Exam)
Para 1 - Definition + Why needed (2 marks)
Define LBC; state limitations of conventional Pap (49% false-negative, 10-20% cell yield, sampling/preparation/interpretive errors).
Para 2 - Technique with flowchart (2 marks)
Collection device → rinse in vial → filter processing → thin monolayer slide → Bethesda reporting. Two systems: ThinPrep and SurePath.
Para 3 - Advantages (2 marks)
80-90% cell yield; eliminates air-drying; reduces unsatisfactory samples by 70-90%; reflex HPV testing; cleaner background; automated reading possible.
Para 4 - Bethesda System / Reporting (2 marks)
NILM, ASC-US, ASC-H, LSIL (CIN1+HPV), HSIL (CIN2+CIN3), AGC, AIS, carcinoma. Management per result.
Para 5 - Screening guidelines + HPV co-testing (1 mark)
ACOG: screen from age 21; LBC ± HPV per age group. Co-testing every 5 years for 30-65 years.
Para 6 - Disadvantages + Clinical applications (1 mark)
More expensive; cells round up; fewer landmarks; special equipment needed; also used for STI testing from same vial.
Sources: Berek & Novak's Gynecology (16th Ed.), p. 844-846 | Histology: A Text and Atlas | Swanson's Family Medicine Review
What is the recent WHO strategy for elimination of cervical cancer ? What is the role of screening and treatment policy for prevention of it 10 mark answer with flowchart,diagrams and proper easy explanation for m.s main exam from berek and novak
Reading File
Now let me run parallel searches - Berek & Novak library + WHO strategy + recent guidelines simultaneously:
Finding Sources
Finding Sources
Searching the Web
WHO 90-70-90 strategy elimination cervical cancer 2030 targets screening treatment
Now let me read the Dermatology textbook section on 90-70-90 and simultaneously dig into Berek & Novak for cervical cancer screening/prevention content:
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching the Web
WHO cervical cancer elimination strategy VIA VILI LEEP LLETZ colposcopy treatment precancer 2023 2024 guidelines
Now let me read the Berek & Novak Cervical Cancer Screening Recommendations section and the cervical cancer chapter:
Reading File
Reading File
Now let me get the treatment of CIN and screen-and-treat sections from Berek & Novak:
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Let me read the Berek & Novak KEY POINTS section and the screening recommendations table:
Reading File
Reading File
I now have comprehensive content from Berek & Novak plus WHO strategy details. Let me compile the full 10-mark exam answer:
WHO Strategy for Elimination of Cervical Cancer
Role of Screening and Treatment | 10-Mark MS Final Exam Answer
Source: Berek & Novak's Gynecology + WHO Global Strategy 2020
INTRODUCTION / EPIDEMIOLOGY
Cervical cancer is the 4th most common cancer in women worldwide. It kills one woman every 2 minutes globally. The WHO Global Strategy (launched November 17, 2020) set a bold target: reduce cervical cancer incidence to fewer than 4 cases per 100,000 women per year - the threshold for elimination as a public health problem.
Berek & Novak: "Screening for cervical cancer precursors using exfoliative cervicovaginal cytology was successful in reducing the incidence of cervical cancer by 79% and the mortality by 70% since 1950."
Key facts:
- Annual incidence: ~600,000 new cases globally (2020)
- Annual deaths: ~342,000 (90% in low/middle-income countries)
- Cervical cancer is entirely preventable - caused by persistent high-risk HPV infection
THE WHO 90-70-90 STRATEGY (2020-2030)
╔══════════════════════════════════════════════════════════════════╗
║ WHO GLOBAL STRATEGY - 90-70-90 TARGETS BY 2030 ║
╠════════════════╦═════════════════════════════════════════════════╣
║ 90% ║ Girls fully VACCINATED with HPV vaccine ║
║ (PRIMARY ║ by age 15 years ║
║ PREVENTION) ║ → 9-valent vaccine (Gardasil 9) ║
╠════════════════╬═════════════════════════════════════════════════╣
║ 70% ║ Women SCREENED with a high-performance ║
║ (SECONDARY ║ test by age 35 AND again by age 45 ║
║ PREVENTION) ║ → HPV DNA test preferred ║
╠════════════════╬═════════════════════════════════════════════════╣
║ 90% ║ Women identified with cervical disease ║
║ (TERTIARY ║ receive TREATMENT ║
║ PREVENTION) ║ → 90% pre-cancer treated ║
║ ║ → 90% invasive cancer managed ║
╚════════════════╩═════════════════════════════════════════════════╝
GOAL: < 4 cases / 100,000 women / year
Mathematical impact if 90-70-90 achieved by 2030:
- Cervical cancer deaths averted: 300,000 by 2030; 14 million by 2070; 62 million by 2120
- Incidence fall: 42% by 2045, 97% by 2120
- 74 million new cases of cervical cancer averted
THREE PILLARS OF THE WHO STRATEGY (FLOWCHART)
╔══════════════════════════════════════════════════════════════════════╗
║ THREE PILLARS OF CERVICAL CANCER ELIMINATION ║
╠══════════════════════════════════════════════════════════════════════╣
║ ║
║ PILLAR 1 PILLAR 2 PILLAR 3 ║
║ PRIMARY SECONDARY TERTIARY ║
║ PREVENTION PREVENTION PREVENTION ║
║ ║
║ HPV VACCINATION SCREENING TREATMENT ║
║ ↓ ↓ ↓ ║
║ Girls 9-14 yrs Women 30-49 yrs CIN 2/3 → Ablation/LEEP ║
║ before sexual (twice lifetime) Invasive Ca → Surgery/ ║
║ debut HPV DNA test Chemoradiation ║
║ ↓ ↓ ↓ ║
║ 90% coverage 70% screened 90% treated ║
║ target target target ║
╚══════════════════════════════════════════════════════════════════════╝
PILLAR 1: HPV VACCINATION (PRIMARY PREVENTION)
Available HPV Vaccines
┌─────────────────────────────────────────────────────────────────┐
│ HPV VACCINES COMPARISON │
├────────────────┬──────────────┬────────────────┬───────────────┤
│ VACCINE │ Bivalent │ Quadrivalent │ 9-valent │
│ │ (Cervarix) │ (Gardasil 4) │ (Gardasil 9) │
├────────────────┼──────────────┼────────────────┼───────────────┤
│ Manufacturer │ GSK │ Merck │ Merck │
│ HPV types │ 16, 18 │ 6,11,16,18 │ 6,11,16,18, │
│ covered │ │ │ 31,33,45,52, │
│ │ │ │ 58 │
│ Cancer │ ~70% │ ~70% │ ~90% │
│ protection │ │ │ of all │
│ │ │ │ cervical Ca │
│ Also prevents │ No │ Genital warts │ Genital warts│
│ │ │ │ + anal Ca │
├────────────────┼──────────────┼────────────────┼───────────────┤
│ Status │ Not in US │ Not in US │ CURRENT │
│ │ market │ market │ STANDARD │
└────────────────┴──────────────┴────────────────┴───────────────┘
Vaccination Schedule (Berek & Novak / CDC)
| Age | Schedule | Doses |
|---|---|---|
| 9-14 years (primary target) | 2-dose: 0, 6-12 months | 2 doses |
| 15-26 years | 3-dose: 0, 2, 6 months | 3 doses |
| 27-45 years | Optional (catch-up) | Shared decision-making |
Key Points (Berek & Novak):
- HPV vaccines contain Virus-Like Particles (VLPs) - NOT live virus
- Strongest immune response before sexual debut (prior HPV exposure)
- Vaccinated women must STILL continue cervical screening
- Herd immunity benefit when males also vaccinated
- Australia: 70% coverage → genital warts nearly disappeared in <21 yrs
- No therapeutic efficacy against pre-existing HPV infection
PILLAR 2: SCREENING (SECONDARY PREVENTION)
Screening Methods Available
┌──────────────────────────────────────────────────────────────────┐
│ CERVICAL CANCER SCREENING TESTS │
├──────────────────────────┬───────────────────────────────────────┤
│ TEST │ FEATURES │
├──────────────────────────┼───────────────────────────────────────┤
│ Conventional Pap Smear │ Sensitivity 47-62% for CIN 2/3 │
│ │ False-negative rate 49% │
│ │ Low cost, widely available │
├──────────────────────────┼───────────────────────────────────────┤
│ Liquid-Based Cytology │ Sensitivity ~81% │
│ (ThinPrep / SurePath) │ Reflex HPV testing possible │
│ │ Unsatisfactory rates ↓70-90% │
├──────────────────────────┼───────────────────────────────────────┤
│ HPV DNA Testing │ Highest sensitivity (>95%) │
│ (PRIMARY SCREEN) │ WHO preferred for women 30-65 │
│ │ Detects high-risk HPV types 16/18+ │
├──────────────────────────┼───────────────────────────────────────┤
│ VIA (Visual Inspection │ Acetic acid applied to cervix │
│ with Acetic Acid) │ White areas = acetowhite = abnormal │
│ │ Low-resource settings; immediate │
│ │ "see and treat" approach │
├──────────────────────────┼───────────────────────────────────────┤
│ VILI (Visual Inspection │ Lugol's iodine applied │
│ with Lugol's Iodine) │ Abnormal = mustard/saffron yellow │
│ │ Normal = mahogany brown │
└──────────────────────────┴───────────────────────────────────────┘
WHO-Recommended Screening Algorithm (Flowchart)
ALL WOMEN 30-49 YEARS
│
↓
┌─── HPV DNA TEST (1st choice) ───┐
│ OR Cytology / VIA │
└──────────────────────────────────┘
│
┌──────────────┴──────────────┐
↓ ↓
HPV NEGATIVE HPV POSITIVE
│ │
↓ ↓
Rescreen in 5 years TRIAGE (Colposcopy /
(2nd screen at age 45) Cytology / VIA)
│
┌─────────────────┴──────────────┐
↓ ↓
NO CIN / CIN 1 CIN 2 / CIN 3
│ │
↓ ↓
Follow-up / Repeat TREATMENT
in 1-3 years (Ablation or LEEP)
ACOG Screening Guidelines (Berek & Novak)
| Age | Recommended Test | Frequency |
|---|---|---|
| < 21 years | No screening | - |
| 21-29 years | Cytology alone | Every 3 years |
| 30-65 years | Co-test (LBC + HPV) | Every 5 years (preferred) |
| 30-65 years | Cytology alone | Every 3 years (acceptable) |
| 30-65 years | Primary HPV testing | Every 5 years (USPSTF) |
| > 65 years | Discontinue | If 3 consecutive negative cytology or 2 negative co-tests in 10 years |
| Post-hysterectomy (benign) | Discontinue | - |
| HIV+/Immunocompromised | Cytology | 2x in year 1, then annually |
| CIN 2+ history | Annual | For 20 years |
PILLAR 3: TREATMENT (TERTIARY PREVENTION)
A. Treatment of Pre-Cancer (CIN)
┌──────────────────────────────────────────────────────────────────┐
│ CIN GRADING AND TREATMENT ALGORITHM │
│ │
│ HISTOLOGY RESULT │
│ │ │
│ ┌────┴────────────────────────────────────┐ │
│ ↓ ↓ ↓ │
│ CIN 1 CIN 2 CIN 3 │
│ │ │ │ │
│ ↓ ↓ ↓ │
│ HPV/LSIL HSIL HSIL │
│ Surveillance TREAT TREAT │
│ 12-24 months ↓ ↓ │
│ (>60% regress) ABLATIVE EXCISIONAL │
│ (if eligible) (preferred) │
│ or ───────────── │
│ EXCISIONAL • LEEP / LLETZ │
│ • Cold Knife Conization │
│ • Laser conization │
└──────────────────────────────────────────────────────────────────┘
Treatment Methods Compared
┌─────────────────────────────────────────────────────────────────────┐
│ TREATMENT MODALITIES FOR CERVICAL PRE-CANCER │
├──────────────────────┬──────────────────────────────────────────────┤
│ ABLATIVE METHODS │ EXCISIONAL METHODS │
│ (Destroys tissue) │ (Removes tissue - preferred) │
├──────────────────────┼──────────────────────────────────────────────┤
│ • Cryotherapy │ • LEEP (Loop Electrosurgical Excision Proc) │
│ • Laser ablation │ = LLETZ (Large Loop Excision Transform. │
│ • Thermal ablation │ Zone) - PREFERRED (Berek & Novak) │
│ • Cold coagulation │ • Cold Knife Conization (CKC) │
├──────────────────────┼──────────────────────────────────────────────┤
│ ELIGIBILITY: │ WHEN EXCISION IS MANDATORY: │
│ • Lesion visible │ • Suspected microinvasive/invasive cancer │
│ • Lesion in TZ │ • Inadequate colposcopy │
│ • No suspicion of │ • Positive ECC │
│ invasion │ • AIS on biopsy │
│ • No pregnancy │ • Ablation failed │
├──────────────────────┼──────────────────────────────────────────────┤
│ Cure rate: ~85-90% │ Cure rate: ~90-95% │
└──────────────────────┴──────────────────────────────────────────────┘
LEEP/LLETZ (Preferred Treatment - Berek & Novak Key Point #15):
"Although CIN 2 and CIN 3 can be treated with a variety of outpatient techniques, the preferred treatment is LEEP. Ablative therapy...is not appropriate if there is evidence of microinvasive or invasive cancer on cytology, colposcopy, endocervical curettage or biopsy."
AIS Treatment (Berek & Novak Key Point #16):
"The preferred management for women who have completed childbearing with histologic diagnosis of AIS is hysterectomy."
B. Treatment of Invasive Cervical Cancer
┌─────────────────────────────────────────────────────────────────┐
│ TREATMENT OF INVASIVE CERVICAL CANCER │
├──────────────────────┬──────────────────────────────────────────┤
│ EARLY STAGE │ ADVANCED STAGE │
│ (IA1, IA2, IB1) │ (IB2, IIA, IIB, III, IV) │
├──────────────────────┼──────────────────────────────────────────┤
│ • Radical │ • Concurrent Chemo-Radiation │
│ Hysterectomy + │ (Cisplatin-based + Radiation) │
│ Pelvic LN │ • External beam + Brachytherapy │
│ dissection │ • Immunotherapy (Pembrolizumab - │
│ OR │ recurrent/metastatic disease) │
│ • Radiation alone │ • Bevacizumab (anti-VEGF) │
│ (for unfit pts) │ │
├──────────────────────┼──────────────────────────────────────────┤
│ For fertility: │ Recurrent disease: │
│ • Radical │ • Pelvic exenteration │
│ trachelectomy │ • Palliative chemotherapy │
│ (IA2, IB1 <2cm) │ │
└──────────────────────┴──────────────────────────────────────────┘
COMPLETE PATHWAY: PREVENTION TO TREATMENT (MASTER FLOWCHART)
╔══════════════════════════════════════════════════════════════════════════╗
║ COMPLETE WHO CERVICAL CANCER ELIMINATION PATHWAY ║
╠══════════════════════════════════════════════════════════════════════════╣
║ ║
║ FEMALE CHILD (9-14 yrs) ║
║ │ ║
║ ↓ ║
║ HPV VACCINATION (Gardasil 9: 2-dose regimen) ║
║ [90% target] Covers HPV 6,11,16,18,31,33,45,52,58 ║
║ │ ║
║ ADOLESCENT/ADULT WOMAN (21+ years) ║
║ │ ║
║ ↓ ║
║ CERVICAL CANCER SCREENING ║
║ Age 21-29: Cytology every 3 years [70% target] ║
║ Age 30-65: HPV DNA + LBC co-test every 5 years (preferred) ║
║ │ ║
║ ┌────┴────────────┐ ║
║ ↓ ↓ ║
║ NEGATIVE POSITIVE ║
║ │ │ ║
║ Routine Colposcopy + Biopsy ║
║ Screening │ ║
║ ┌────┴──────────────────────┐ ║
║ ↓ ↓ ║
║ CIN 1 CIN 2 / CIN 3 ║
║ │ │ ║
║ Surveillance TREATMENT ║
║ (60% regress) [90% target] ║
║ ┌────────────────┐ ║
║ ↓ ↓ ║
║ ABLATION LEEP/LLETZ ║
║ (if eligible) (PREFERRED) ║
║ │ │ ║
║ └────────────────┘ ║
║ │ ║
║ POST-TREATMENT ║
║ SURVEILLANCE ║
║ │ ║
║ ┌───────────────┴──────────────┐ ║
║ ↓ ↓ ║
║ CLEAR/CURED INVASIVE CANCER ║
║ Rescreen in ↓ ║
║ 3-5 years Surgery / Chemo-RT ║
║ / Immunotherapy ║
╚══════════════════════════════════════════════════════════════════════════╝
SCREEN-AND-TREAT APPROACH (Low-Resource Settings)
For low/middle-income countries (WHO recommendation):
┌──────────────────────────────────────────────────────────────────┐
│ SCREEN-AND-TREAT ALGORITHM (WHO 2021) │
│ │
│ SCREEN WITH: POSITIVE TREAT IMMEDIATELY │
│ VIA / HPV test ──────────────→ (Same visit if VIA+) │
│ │
│ VIA POSITIVE → Thermal ablation (same visit) OR LEEP │
│ HPV+ + VIA+ → Thermal ablation or LEEP │
│ HPV+ + VIA- → Colposcopy/cytology triage before treat │
│ │
│ ADVANTAGE: Single visit - reduces loss to follow-up │
│ Especially useful in resource-limited settings │
└──────────────────────────────────────────────────────────────────┘
ASC-US TRIAGE FLOWCHART (ALTS Trial - Berek & Novak)
ASC-US ON CYTOLOGY
│
┌────────────┼────────────────┐
↓ ↓ ↓
Immediate HPV Reflex Repeat Pap
Colposcopy Testing in 6 months
(most (PREFERRED) (least sensitive)
sensitive) │
┌────┴────┐
↓ ↓
HPV -ve HPV +ve
│ │
↓ ↓
Routine Colposcopy
Screen (Sensitivity 96%
for CIN 2/3)
ALTS Trial Key Data (Berek & Novak):
- HPV test sensitivity for CIN 2: 95.9%
- HPV test sensitivity for CIN 3: 96.3%
- 80% of ASC-US women have NO significant lesion on colposcopy
CERVICAL CARCINOGENESIS (Understanding the Biology)
NORMAL CERVIX
↓ (HPV 16/18 infection - 50× ↑ risk)
HPV INFECTION (clears in 80% within 2 years)
↓ (10-20% persist → risk factor: smoking, immunosuppression, OCP)
CIN 1 (LSIL) → 60% spontaneous regression
↓
CIN 2 (HSIL) → 40% regression, 20% progress
↓
CIN 3 (HSIL) → Carcinoma in situ
↓ (average 10-15 years)
INVASIVE CARCINOMA
Risk Factors (Berek & Novak):
- HPV types 16/18 → 50-fold increased risk for precancerous lesions
- Early sexual debut + multiple partners
- Immunosuppression (HIV: screen twice/year 1, then annually)
- Smoking
- Long-term OCP use (RR 2.2 at >10 years)
- Lack of screening (>50% invasive cancer in never-screened women)
IMPACT OF 90-70-90 STRATEGY (Summary Diagram)
┌─────────────────────────────────────────────────────────────────┐
│ PROJECTED IMPACT IF 90-70-90 TARGETS MET BY 2030 │
├────────────────────────┬────────────────────────────────────────┤
│ Timeline │ Benefit │
├────────────────────────┼────────────────────────────────────────┤
│ By 2030 │ 300,000 deaths averted │
│ By 2045 │ 42% fall in incidence │
│ By 2070 │ 14 million deaths averted │
│ By 2120 │ 97% fall in incidence │
│ │ 62 million deaths averted │
│ │ 74 million new cases averted │
├────────────────────────┼────────────────────────────────────────┤
│ Also contributes to: │ SDG 1 (poverty elimination), │
│ │ SDG 3 (health & well-being), │
│ │ SDG 5 (gender equality) │
└────────────────────────┴────────────────────────────────────────┘
HIGH-YIELD KEY POINTS (Quick Revision)
| # | Point |
|---|---|
| 1 | WHO 90-70-90 launched November 2020; goal: <4 cases/100,000/year |
| 2 | Three pillars: Vaccination → Screening → Treatment |
| 3 | Gardasil 9 covers 9 HPV types → ~90% of cervical cancers |
| 4 | HPV vaccines are VLPs - NOT live virus; NO therapeutic effect on existing HPV |
| 5 | Vaccinate GIRLS before sexual debut (age 9-14); 2-dose regimen |
| 6 | Screen women TWICE: at age 35 AND age 45 (minimum WHO recommendation) |
| 7 | HPV DNA test is the preferred primary screening modality (highest sensitivity >95%) |
| 8 | LEEP/LLETZ is the preferred treatment for CIN 2/3 (Berek & Novak) |
| 9 | CIN 1 = surveillance; CIN 2/3 = active treatment (not watchful waiting) |
| 10 | AIS → hysterectomy (preferred after completing childbearing) |
| 11 | Screen-and-treat (VIA + same-visit ablation) for low-resource countries |
| 12 | ASC-US → Reflex HPV testing; HPV+ → colposcopy |
EXAM MEMORY AID
WHO 90-70-90 = "VaccScreen-Treat"
┌──────────────────────────────────────────────────────┐
│ 90% Vaccinated → Girls age 9-14, Gardasil 9 │
│ 70% Screened → Women 35+45 yrs, HPV DNA test │
│ 90% Treated → CIN2/3 → LEEP; Invasive → Surgery│
│ │
│ TARGET: < 4/100,000/year = ELIMINATION │
└──────────────────────────────────────────────────────┘
10-MARK ANSWER STRUCTURE
Para 1 - Introduction + WHO global burden (1 mark): 4th most common cancer; 600,000/year; one death every 2 minutes; 90% in LMICs; entirely preventable.
Para 2 - WHO 90-70-90 strategy + definition of elimination (2 marks): Launched 2020; three targets by 2030; elimination = <4/100,000/year; projected 62 million deaths averted.
Para 3 - Pillar 1: Vaccination (2 marks): Gardasil 9 (9-valent VLP vaccine); HPV types covered; 2-dose/3-dose schedules; VIA analogy; must continue screening after vaccination.
Para 4 - Pillar 2: Screening (2 marks): Methods (VIA/VILI/Cytology/LBC/HPV DNA); ACOG guidelines table; HPV DNA as primary screen; co-testing; ASC-US triage with ALTS trial data.
Para 5 - Pillar 3: Treatment (2 marks): CIN grading; ablative vs. excisional methods; LEEP as preferred (Berek & Novak); AIS → hysterectomy; invasive cancer → stage-based management; screen-and-treat for LMICs.
Para 6 - Impact + Conclusion (1 mark): Projected impact statistics; SDG goals; "Only cancer for which we have all three primary/secondary/tertiary prevention tools."
Sources: Berek & Novak's Gynecology (16th Ed.), Chapter 16, pp. 833-848 | WHO Global Strategy to Accelerate the Elimination of Cervical Cancer (2020) | Dermatology 5e (Gardasil 9 section) | WHO Guideline for Screening and Treatment of Cervical Pre-Cancer Lesions (2021 update)
Discusss the management of stage 1b cervical cancer 10 mark answer with flowchart diagrams with easy explanation for ms main exam berek and novak
Finding Sources
Finding Sources
Searching the Web
Stage IB cervical cancer management radical hysterectomy chemoradiation FIGO 2018 staging Berek Novak
Good. Now let me read the Berek & Novak treatment-by-stage section directly and search for radical hysterectomy details:
Reading File
Finding Sources
Finding Sources
Excellent! The read_file returned rich content. Let me now read more - the IB3 section and the radical hysterectomy classification:
Reading File
Reading File
Now let me get the radical hysterectomy types classification and post-op adjuvant therapy sections:
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive, detailed content directly from Berek & Novak. Let me compile the complete 10-mark answer:
Management of Stage IB Cervical Cancer
10-Mark MS Final Exam Answer | Source: Berek & Novak's Gynecology
INTRODUCTION: FIGO 2018 STAGING OF STAGE IB
The 2018 FIGO staging (revised by Bhatla, Berek et al., Int J Gynecol Obstet 2019) subdivided Stage IB into THREE substages based on tumor size. This is the currently used classification.
╔══════════════════════════════════════════════════════════════════════╗
║ FIGO 2018 STAGE IB - DEFINITION AND SUBSTAGES ║
╠══════════════════════════════════════════════════════════════════════╣
║ ║
║ STAGE IB = Invasive carcinoma with deepest invasion ≥5 mm ║
║ CONFINED TO THE CERVIX UTERI ║
║ ║
║ ┌─────────┬──────────────────────────────────────────────────────┐ ║
║ │ IB1 │ Stromal invasion ≥5 mm AND tumor <2 cm │ ║
║ │ │ 5-year survival: 91.6% │ ║
║ ├─────────┼──────────────────────────────────────────────────────┤ ║
║ │ IB2 │ Tumor ≥2 cm AND <4 cm in greatest dimension │ ║
║ │ │ 5-year survival: 83.3% │ ║
║ ├─────────┼──────────────────────────────────────────────────────┤ ║
║ │ IB3 │ Tumor ≥4 cm in greatest dimension ("Bulky") │ ║
║ │ │ 5-year survival: 76.1% │ ║
║ └─────────┴──────────────────────────────────────────────────────┘ ║
║ ║
║ NOTE: LVSI must be documented but does NOT alter FIGO stage ║
╚══════════════════════════════════════════════════════════════════════╝
Compare to OLD FIGO 2009:
- Old IB1 = ≤4 cm → now split into IB1 (<2 cm) and IB2 (2-4 cm)
- Old IB2 = >4 cm → now called IB3
PRE-TREATMENT WORKUP
┌─────────────────────────────────────────────────────────────────┐
│ WORKUP BEFORE TREATING STAGE IB │
├─────────────────────────────────────────────────────────────────┤
│ CLINICAL ASSESSMENT: │
│ • History + Physical examination │
│ • Pelvic exam under anaesthesia (EUA) │
│ • Cervical biopsy / cone biopsy for histology │
│ │
│ LABORATORY: │
│ • CBC, LFT, RFT, blood grouping │
│ • SCC antigen (squamous cell carcinoma marker) │
│ │
│ IMAGING: │
│ • MRI pelvis (best for tumor size, parametrium, nodes) │
│ • CT chest-abdomen-pelvis (metastatic disease) │
│ • PET/CT scan (lymph node assessment - para-aortic) │
│ • Cystoscopy / Proctoscopy (if bladder/rectal involvement │
│ suspected) │
│ │
│ KEY FACTORS THAT DETERMINE MANAGEMENT: │
│ 1. Tumor SIZE (IB1 vs IB2 vs IB3) │
│ 2. Fertility DESIRE │
│ 3. Lymph node STATUS (PET/CT/surgical) │
│ 4. LVSI status │
│ 5. Histologic TYPE (squamous vs adenocarcinoma) │
│ 6. Patient fitness for surgery │
└─────────────────────────────────────────────────────────────────┘
MASTER MANAGEMENT FLOWCHART
╔═══════════════════════════════════════════════════════════════════════════╗
║ MANAGEMENT OF STAGE IB CERVICAL CANCER ║
║ (Berek & Novak, FIGO 2018) ║
╠═══════════════════════════════════════════════════════════════════════════╣
║ ║
║ STAGE IB ║
║ │ ║
║ ┌─────────────┼─────────────┐ ║
║ ↓ ↓ ↓ ║
║ IB1 IB2 IB3 ║
║ (<2 cm) (2-4 cm) (≥4 cm) ║
║ │ │ │ ║
║ ↓ ↓ ↓ ║
║ FERTILITY NO RADICAL PRIMARY ║
║ DESIRED? FERTILITY HYSTERECTOMY CHEMORADIATION ║
║ │ DESIRE TYPE III + (PREFERRED) ║
║ │ │ PLND │ ║
║ ↓ ↓ │ ↓ ║
║ RADICAL RADICAL │ CCRT (Cisplatin ║
║ TRACHEL- HYSTER- │ weekly + ║
║ ECTOMY ECTOMY │ External Beam RT ║
║ + PLND TYPE III │ + Brachytherapy) ║
║ │ + PLND │ │ ║
║ │ │ │ ↓ ║
║ └──────┴──────────┘ OR: Radical Hyst. ║
║ │ Type III + PLND ║
║ ↓ + Para-aortic LN ║
║ PATHOLOGY REVIEW dissection ║
║ OF SPECIMEN + Adjuvant CRT ║
║ │ if high-risk features ║
║ ┌──────────┴──────────┐ ║
║ ↓ ↓ ║
║ LOW/INTER- HIGH-RISK ║
║ MEDIATE RISK FEATURES ║
║ │ │ ║
║ ↓ ↓ ║
║ Surveillance Adjuvant ║
║ /Observation CHEMORADIATION ║
║ (Cisplatin + ║
║ 5-FU + RT) ║
╚═══════════════════════════════════════════════════════════════════════════╝
TREATMENT OPTION 1: RADICAL HYSTERECTOMY
Types of Hysterectomy (Querleu-Morrow / Piver Classification)
┌──────────────────────────────────────────────────────────────────────┐
│ TYPES OF HYSTERECTOMY (Berek & Novak) │
├────────┬──────────────────────────────────────────────────────────────┤
│ TYPE │ DESCRIPTION │
├────────┼──────────────────────────────────────────────────────────────┤
│ TYPE I │ Extrafascial (Simple) Hysterectomy │
│ │ • Uterus removed outside fascial capsule │
│ │ • No parametrium removed │
│ │ • Used for CIN 3, Stage IA1 (no LVSI) │
├────────┼──────────────────────────────────────────────────────────────┤
│ TYPE II│ Modified Radical (Wertheim's) Hysterectomy │
│ │ • Medial ½ of cardinal + uterosacral ligaments │
│ │ • Uterine artery ligated at level of ureter │
│ │ • Small vaginal margin │
│ │ • + Pelvic LN dissection │
│ │ • Used for: Stage IA2, early IB1 │
├────────┼──────────────────────────────────────────────────────────────┤
│TYPE III│ RADICAL (Meigs') Hysterectomy ← STANDARD FOR IB │
│ │ • Entire cardinal + uterosacral ligaments │
│ │ • Upper 1/3 vagina removed │
│ │ • Uterine artery ligated at origin │
│ │ • Complete ureteral unroofing │
│ │ + Bilateral pelvic lymphadenectomy │
│ │ Used for: Stage IB1, IB2, IIA1 │
├────────┼──────────────────────────────────────────────────────────────┤
│ TYPE IV│ Extended Radical Hysterectomy │
│ │ • + periureteral tissue + superior vesical artery │
│ │ • + 3/4 vagina │
│ │ • Rarely used (RT preferred) │
├────────┼──────────────────────────────────────────────────────────────┤
│ TYPE V │ Partial Exenteration │
│ │ • + distal ureter + bladder portions │
│ │ • Very rarely performed │
└────────┴──────────────────────────────────────────────────────────────┘
What is Removed in Type III Radical Hysterectomy?
┌─────────────────────────────────────────────────────────────────┐
│ TYPE III RADICAL HYSTERECTOMY - SPECIMEN INCLUDES │
│ │
│ ✓ Uterus (with cervix) │
│ ✓ Bilateral fallopian tubes │
│ ✓ Bilateral ovaries (optional - can preserve in young women) │
│ ✓ ENTIRE cardinal ligaments (to pelvic sidewall) │
│ ✓ ENTIRE uterosacral ligaments │
│ ✓ Upper 1/3 of vagina │
│ ✓ Bilateral pelvic lymph nodes (obturator, internal iliac, │
│ external iliac, common iliac) │
│ ✓ Para-aortic LN assessment (if pelvic nodes positive) │
│ │
│ KEY STEP: Ureter is completely unroofed/dissected out of │
│ the paracervical tunnel ("ureter in the clamp" - B&N Fig 38-7) │
└─────────────────────────────────────────────────────────────────┘
Approach Options for Radical Hysterectomy
| Approach | Notes |
|---|---|
| Open (abdominal) | Gold standard; Meigs operation (1944) |
| Laparoscopic | MIS; comparable outcomes in IB1 |
| Robotic | Gaining popularity; good for trachelectomy |
| LARAID Trial | Minimally invasive radical hyst. had worse OS vs. open for tumors >2cm - caution advised |
TREATMENT OPTION 2: RADICAL TRACHELECTOMY (Fertility-Sparing)
Berek & Novak: "Radical trachelectomy is a procedure that is gaining popularity as a surgical management option for women with stage IA2 and IB1 disease who desire uterine preservation and fertility."
┌───────────────────────────────────────────────────────────────────┐
│ RADICAL TRACHELECTOMY - KEY FACTS │
├───────────────────────────────────────────────────────────────────┤
│ DEFINITION: Removal of cervix + parametrium + upper vagina │
│ while PRESERVING the uterine corpus │
│ │
│ ELIGIBILITY CRITERIA (all must be met): │
│ • Tumor size ≤ 2 cm (IB1) │
│ • NO lymph node metastases │
│ • NO lymphovascular space invasion (LVSI) │
│ • Potential to preserve upper cervix (>5mm negative margin) │
│ • Strong desire for future fertility │
│ + Pelvic lymphadenectomy always performed │
│ │
│ APPROACHES: │
│ Vaginal (Dargent) / Abdominal / Laparoscopic / Robotic │
│ │
│ OUTCOMES (B&N): │
│ • 5-year cumulative pregnancy rate: 52.8% after trachelectomy │
│ • Increased risk of miscarriage │
│ • 10% second trimester loss │
│ • 72% carry to ≥37 weeks │
│ • If recurrence: switch to definitive surgery or radiation │
└───────────────────────────────────────────────────────────────────┘
TREATMENT OPTION 3: PRIMARY CHEMORADIATION (CCRT)
Components of Radiation Therapy
┌──────────────────────────────────────────────────────────────────┐
│ RADIATION THERAPY FOR CERVICAL CANCER │
├────────────────────────────┬─────────────────────────────────────┤
│ EXTERNAL BEAM RT (EBRT) │ BRACHYTHERAPY (Internal RT) │
├────────────────────────────┼─────────────────────────────────────┤
│ • 45-50 Gy to whole │ • Intracavitary radiation │
│ pelvis │ • Ring-and-tandem / Manchester │
│ • 4-6 weeks │ system / Fletcher applicator │
│ • Treats primary tumor │ • Boosts central tumor dose │
│ + pelvic lymph nodes │ • Prescribed to point A and │
│ • ± Extended field if │ point B │
│ para-aortic nodes +ve │ │
└────────────────────────────┴─────────────────────────────────────┘
Concurrent Chemotherapy - Evidence (Berek & Novak GOG Trials)
┌────────────────────────────────────────────────────────────────────┐
│ KEY GOG TRIALS (Berek & Novak) │
├──────────────┬─────────────────────────────────────────────────────┤
│ GOG-85 │ Stage IIB-IVA: Cisplatin+5-FU+RT │
│ │ vs Hydroxyurea+RT │
│ │ → CCRT superior (PFS + OS) │
├──────────────┼─────────────────────────────────────────────────────┤
│ GOG-120 │ Stage IIB-IVA: Weekly cisplatin + RT │
│ │ vs Cisplatin+5FU+HU+RT │
│ │ vs HU+RT │
│ │ → Both cisplatin arms superior │
│ │ → Relative risk of death ↓ 0.55-0.57 │
├──────────────┼─────────────────────────────────────────────────────┤
│ GOG │ Stage IB-IVA: CCRT vs RT alone │
│ (3rd trial) │ → 5-yr survival: 73% (CCRT) vs 58% (RT alone) │
│ │ → Disease-free survival: 67% vs 40% │
├──────────────┼─────────────────────────────────────────────────────┤
│ BULKY IB │ Bulky IB: Cisplatin+RT vs RT alone │
│ GOG study │ → 3-yr survival: 83% vs 74% │
│ │ → Adjuvant hysterectomy after CCRT did NOT │
│ │ improve survival further │
└──────────────┴─────────────────────────────────────────────────────┘
CONCLUSION (Berek & Novak):
"Cisplatin-based concurrent chemoradiation is the treatment of choice."
Standard Chemotherapy Regimen:
- Weekly Cisplatin 40 mg/m² IV during radiation (most common)
- OR Cisplatin 50 mg/m² + 5-FU 4-day infusion (every 3 weeks)
ADJUVANT THERAPY AFTER RADICAL HYSTERECTOMY
Risk Factor Classification (Sedlis Criteria + High-Risk Criteria)
╔══════════════════════════════════════════════════════════════════╗
║ RISK STRATIFICATION AFTER RADICAL HYSTERECTOMY ║
╠═════════════════════════════════╦════════════════════════════════╣
║ INTERMEDIATE RISK ║ HIGH RISK ║
║ (Sedlis Criteria) ║ (Peters Criteria) ║
╠═════════════════════════════════╬════════════════════════════════╣
║ ANY 2 of the following: ║ ANY 1 of the following: ║
║ • LVSI positive ║ • Positive pelvic lymph nodes║
║ • Deep stromal invasion ║ • Positive surgical margins ║
║ • Large tumor size ║ • Positive parametrium ║
╠═════════════════════════════════╬════════════════════════════════╣
║ TREATMENT: ║ TREATMENT: ║
║ Adjuvant PELVIC RADIATION ║ Adjuvant CHEMORADIATION ║
║ → 47% ↓ in recurrent disease ║ → 4-yr OS: 81% (CRT) ║
║ (GOG randomised trial) ║ vs 71% (RT alone) ║
╚═════════════════════════════════╩════════════════════════════════╝
Berek & Novak: "In patients with stage IA2, IB, and IIA cervical cancer with high-risk features after radical hysterectomy (positive pelvic lymph nodes, positive parametrial extension, or positive vaginal margins), chemoradiation is the postoperative treatment of choice."
SURGERY vs. RADIATION - EQUIVALENCE DATA
┌──────────────────────────────────────────────────────────────────┐
│ RADICAL HYSTERECTOMY vs. RADIOTHERAPY - COMPARISON │
├─────────────────────────────────┬────────────────────────────────┤
│ RADICAL HYSTERECTOMY + PLND │ CHEMORADIATION │
├─────────────────────────────────┼────────────────────────────────┤
│ ADVANTAGES: │ ADVANTAGES: │
│ • Complete surgical staging │ • Avoids surgery │
│ • Ovarian conservation │ • No anaesthetic risk │
│ • Histology confirms │ • Suitable for unfit patients │
│ completeness │ • Avoids combined morbidity │
│ • Better vaginal function │ │
│ • Avoids radiation sequelae │ │
├─────────────────────────────────┼────────────────────────────────┤
│ DISADVANTAGES: │ DISADVANTAGES: │
│ • Combined morbidity if │ • Premature menopause │
│ adjuvant RT needed │ • Radiation complications │
│ • Bladder/bowel dysfunction │ • Cannot preserve ovaries │
│ • Lymphedema │ • Vaginal stenosis │
│ • Ureter fistula (rare) │ • Radiation fibrosis/bowel │
├─────────────────────────────────┼────────────────────────────────┤
│ SURVIVAL: EQUAL for IB1/IB2 │ SURVIVAL: EQUAL for IB1/IB2 │
└─────────────────────────────────┴────────────────────────────────┘
IMPORTANT (Berek & Novak): "Patients treated with Type III radical
hysterectomy who subsequently received postoperative radiation had
a HIGHER rate of intestinal and urinary morbidity compared with
patients treated with either modality ALONE."
→ Avoid bimodality treatment when possible
→ For IB3: primary CCRT preferred to avoid dual-modality morbidity
COMPLETE STAGE-BY-STAGE MANAGEMENT (IB1, IB2, IB3)
Stage IB1 (<2 cm)
┌─────────────────────────────────────────────────────────────────┐
│ STAGE IB1 (<2 cm) │
│ │
│ FERTILITY DESIRED? │
│ │ │
│ YES ↓ NO ↓ │
│ │
│ RADICAL TRACHELECTOMY TYPE III RADICAL HYSTERECTOMY │
│ + Pelvic LN dissection + Bilateral Pelvic LND │
│ (Vaginal/Abdominal/Robotic) (Abdominal / Laparoscopic) │
│ │ OR │
│ │ PRIMARY CHEMORADIATION │
│ │ │
│ ↓ ↓ │
│ Post-op pathology Post-op pathology │
│ review: review: │
│ • If negative: surveillance • Low risk: surveillance │
│ • If positive nodes/margins: • Inter. risk: pelvic RT │
│ RT/CRT • High risk: CCRT │
└─────────────────────────────────────────────────────────────────┘
Stage IB2 (2-4 cm)
┌─────────────────────────────────────────────────────────────────┐
│ STAGE IB2 (2-4 cm) │
│ │
│ TYPE III RADICAL HYSTERECTOMY + PLND (+ para-aortic LND │
│ if pelvic nodes positive) │
│ OR │
│ PRIMARY CHEMORADIATION (cisplatin weekly + EBRT + brachy) │
│ │
│ → Both modalities give EQUIVALENT survival │
│ → Choose based on: patient fitness, desire for ovarian │
│ conservation, risk of needing adjuvant RT │
│ │
│ POST-OP ADJUVANT (if radical hysterectomy done): │
│ • Intermediate risk → pelvic RT (↓ recurrence by 47%) │
│ • High risk (+ LN, + margins, + parametrium) → CCRT │
└─────────────────────────────────────────────────────────────────┘
Stage IB3 (≥4 cm - "Bulky")
┌──────────────────────────────────────────────────────────────────┐
│ STAGE IB3 (≥4 cm - BULKY) │
│ │
│ PRIMARY CHEMORADIATION → STRONGLY PREFERRED │
│ (Concurrent weekly cisplatin + EBRT + Brachytherapy) │
│ │
│ RATIONALE (Berek & Novak): │
│ "Many of these patients will have intermediate- or high-risk │
│ factors postoperatively, so strong consideration should be │
│ given to primary chemoradiation." │
│ │
│ IF SURGERY DESIRED: │
│ Type III radical hysterectomy + pelvic AND para-aortic LND │
│ → Followed by adjuvant CCRT if risk factors present │
│ → High morbidity from bimodal treatment │
│ │
│ NOTE: Adjuvant hysterectomy AFTER CCRT does NOT improve │
│ survival (GOG bulky IB trial - B&N) │
│ │
│ 3-year OS with CCRT: 83% │
│ 3-year OS with RT alone: 74% │
└──────────────────────────────────────────────────────────────────┘
COMPLICATIONS OF RADICAL HYSTERECTOMY
┌──────────────────────────────────────────────────────────────────┐
│ COMPLICATIONS OF TYPE III RADICAL HYSTERECTOMY │
├──────────────────────────────┬───────────────────────────────────┤
│ INTRAOPERATIVE │ POSTOPERATIVE │
├──────────────────────────────┼───────────────────────────────────┤
│ • Hemorrhage │ EARLY: │
│ • Ureteric injury │ • Bladder dysfunction (common) │
│ • Bladder injury │ • Urinary retention │
│ • Bowel injury │ • DVT/Pulmonary embolism │
│ • Vascular injury │ • Wound infection │
│ (iliac vessels) │ • Lymphocyst formation │
│ │ LATE: │
│ │ • Lymphedema │
│ │ • Ureteric fistula (rare) │
│ │ • Vesicovaginal fistula │
│ │ • Sexual dysfunction │
│ │ • Bowel complications (if +RT) │
└──────────────────────────────┴───────────────────────────────────┘
LYMPH NODE INVOLVEMENT - PROGNOSTIC IMPACT
| Lymph Node Status | 5-year Survival | Notes |
|---|---|---|
| Negative nodes | ~85-90% | Excellent prognosis |
| 1-3 positive pelvic nodes | ~59-60% | Adjuvant RT beneficial |
| >3 positive pelvic nodes | <50% | Extended-field RT ± CCRT |
| Common iliac nodes positive | ~20% | Poor prognosis |
| Para-aortic nodes positive | ~15-26% | Extended-field RT; 20-50% if microscopic |
Berek & Novak: "Nodal involvement, particularly the para-aortic lymph nodes, is the most important factor related to survival."
SURVEILLANCE AFTER TREATMENT
┌─────────────────────────────────────────────────────────────────┐
│ POST-TREATMENT FOLLOW-UP SCHEDULE │
├────────────────────┬────────────────────────────────────────────┤
│ Years 1-2 │ Every 3 months │
│ Years 3-5 │ Every 6 months │
│ After 5 years │ Annually │
├────────────────────┼────────────────────────────────────────────┤
│ Each visit: │ • Pelvic examination │
│ │ • Vault smear │
│ │ • SCC antigen if elevated pre-treatment │
│ │ • CT/PET-CT if symptoms │
└────────────────────┴────────────────────────────────────────────┘
HIGH-YIELD SUMMARY TABLE
| Stage | Tumor Size | Primary Treatment | Adjuvant |
|---|---|---|---|
| IB1 | <2 cm | Radical hyst. (Type III) + PLND OR CCRT | Based on risk factors |
| IB1 + Fertility | <2 cm | Radical trachelectomy + PLND | If recurrence: radical Rx |
| IB2 | 2-4 cm | Radical hyst. (Type III) + PLND OR CCRT (equivalent) | Int. risk: RT; High risk: CCRT |
| IB3 | ≥4 cm | Primary CCRT PREFERRED | Avoid dual modality |
| Any IB + positive LN/margins post-op | - | Adjuvant CCRT (Cisplatin + 5-FU + RT) | 4-yr OS 81% vs 71% (RT alone) |
EXAM MEMORY AID
Stage IB Management = "TRACH-TYIII-CCRT"
┌─────────────────────────────────────────────────────────────────┐
│ IB1 (<2cm) = Trachelectomy (if fertility) OR Type III RH │
│ IB2 (2-4cm) = Type III RH + PLND ↔ CCRT (equivalent OS) │
│ IB3 (≥4cm) = Primary CCRT preferred (avoid dual-modality) │
│ │
│ Type III RH = Meigs 1944 = uterosacral + cardinal + PLND │
│ Cisplatin weekly = standard chemo concurrent with RT │
│ High-risk post-op = + nodes / + margins / + parametrium │
│ → POST-OP CCRT (81% vs 71% OS) │
│ Best prognostic factor = lymph node status │
└─────────────────────────────────────────────────────────────────┘
10-MARK ANSWER STRUCTURE
Para 1 - FIGO 2018 staging + definition (1 mark): IB defined; three substages IB1/IB2/IB3 with size criteria; survival rates; LVSI notation.
Para 2 - Workup (1 mark): Clinical, lab, imaging (MRI/CT/PET-CT); key determinant factors (size, fertility, nodes).
Para 3 - Treatment of IB1 with flowchart (2 marks): Radical trachelectomy (fertility) vs Type III radical hysterectomy + PLND; post-op risk stratification.
Para 4 - Types of radical hysterectomy table (2 marks): Type I to V comparison; what is removed in Type III (Meigs operation - uterosacral, cardinal, upper 1/3 vagina, pelvic LN).
Para 5 - Treatment of IB3 / bulky disease (2 marks): Primary CCRT preferred; GOG trial evidence (3-yr OS 83% CCRT vs 74% RT); adjuvant hysterectomy after CCRT does NOT help.
Para 6 - Adjuvant therapy after surgery / complications (2 marks): Sedlis (intermediate risk) → pelvic RT; Peters (high risk: +LN, +margins, +parametrium) → CCRT; complication table.
Sources: Berek & Novak's Gynecology (16th Ed.), Chapter 38, pp. 2240-2268 | FIGO 2018 Staging (Bhatla, Berek et al., 2019)
What is lvsi status?
LVSI stands for Lymphovascular Space Invasion (also called Lymph-Vascular Space Invasion).
It means tumor cells have invaded into the lymphatic channels or small blood vessels (capillaries/venules) within the cervical stroma - visible on histology of the biopsy or surgical specimen.
Searching sources...
Finding Sources
Finding Sources
Finding Sources
Here is a clear, complete explanation:
LVSI - Lymphovascular Space Invasion
What Is It?
LVSI = Lymphovascular Space Invasion (sometimes written as CLSI = Capillary Lymphatic Space Invasion in older literature, as used by Berek & Novak).
It refers to the presence of tumor cells inside the lumen of lymphatic channels or small blood capillaries within the cervical stroma, as seen on histopathological examination of a biopsy or surgical specimen.
Simple Analogy
Think of lymph vessels and capillaries as drainage pipes inside the cervix. Normally, only fluid and blood cells flow through them. When LVSI is present, cancer cells have broken into these pipes and can now travel to lymph nodes and distant sites - just like sending parcels through a delivery network.
Normal: Cervical stroma → Lymph vessel → Clean (fluid only)
LVSI present: Cervical stroma → Lymph vessel → Tumor cell clusters
↓
LYMPH NODE METASTASIS RISK ↑
How Is LVSI Detected?
- Seen on H&E stained histology slides after biopsy/LEEP/cone/radical hysterectomy specimen
- Pathologist identifies clusters of malignant cells inside thin-walled vascular/lymphatic channels in the stroma
- Reported as: LVSI positive or LVSI negative
- FIGO 2018 requires LVSI to be documented in the pathology report for every cervical cancer specimen
Why Does LVSI Matter? (Clinical Significance)
┌──────────────────────────────────────────────────────────────────┐
│ CLINICAL SIGNIFICANCE OF LVSI │
├──────────────────────────────────────────────────────────────────┤
│ 1. STAGING IMPACT (FIGO 2018) │
│ LVSI does NOT change the FIGO stage number │
│ BUT must be documented and reported │
│ │
│ 2. PROGNOSIS │
│ LVSI positive → ↑ risk of lymph node metastasis │
│ → ↑ risk of recurrence │
│ → ↓ overall survival │
│ │
│ 3. TREATMENT DECISIONS │
│ a) Stage IA1 + LVSI → Upgrade treatment: │
│ → Type I or II hysterectomy + pelvic LN dissection │
│ (would otherwise be simple hysterectomy/cone only) │
│ │
│ b) Stage IB1 + LVSI → Does NOT qualify for │
│ radical trachelectomy (fertility-sparing surgery) │
│ │
│ c) Post-radical hysterectomy: LVSI is one of the │
│ INTERMEDIATE RISK factors (Sedlis Criteria) │
│ → If present with other factors → adjuvant pelvic RT │
└──────────────────────────────────────────────────────────────────┘
LVSI in the Sedlis Criteria (Post-Op Risk Stratification)
As mentioned in the Stage IB management notes, after radical hysterectomy, LVSI is one of three factors in the Sedlis (GOG) intermediate risk criteria:
┌──────────────────────────────────────────────────────────────┐
│ SEDLIS CRITERIA (Intermediate Risk) │
│ │
│ Any COMBINATION of 2 or more of: │
│ 1. LVSI positive ← (this is LVSI status) │
│ 2. Deep stromal invasion (>1/3 thickness) │
│ 3. Large tumor size (≥4 cm) │
│ │
│ If met → Adjuvant PELVIC RADIOTHERAPY recommended │
│ GOG trial showed 47% reduction in recurrent disease │
└──────────────────────────────────────────────────────────────┘
Summary
| Feature | Detail |
|---|---|
| Full form | Lymphovascular Space Invasion |
| Detected by | Histopathology (H&E stain) |
| Meaning | Tumor cells inside lymph vessels/capillaries |
| FIGO stage effect | Does NOT change stage but MUST be reported |
| Stage IA1 + LVSI | Needs pelvic lymph node dissection |
| IB1 + LVSI | Ineligible for radical trachelectomy |
| Post-op LVSI | Intermediate risk factor → may need adjuvant RT |
| Prognosis | LVSI positive = worse prognosis; higher recurrence |
In one sentence: LVSI positive means cancer has begun its journey into the lymphatic/vascular system of the cervix, making it more likely to spread to lymph nodes and distant sites, which directly influences how aggressively it must be treated.
Discuss recent changes in FIGO staging of cervical cancer from berek and novak 10mark answer with flow chart and diagrams
Finding Sources
Finding Sources
Searching the Web
FIGO 2018 cervical cancer staging changes from 2009 lymph node IIIc new substages summary
Found the Berek & Novak staging section. Let me read it directly along with the old 2008 staging table:
Reading File
Finding Sources
The read_file captured a huge amount. Let me read more to get the old 2008 table and additional staging notes:
Reading File
I now have all the key content directly from Berek & Novak. Let me also get the old 2008 FIGO table and imaging modalities comparison:
Reading File
Finding Sources
I now have both the 2008 (old) and 2018 (new) FIGO staging tables directly from Berek & Novak, plus all the footnotes and explanatory text. I have everything needed for a comprehensive 10-mark answer.
Recent Changes in FIGO Staging of Cervical Cancer
10-Mark MS Final Exam Answer | Source: Berek & Novak's Gynecology (Chapter 38)
INTRODUCTION
The International Federation of Gynecology and Obstetrics (FIGO) staging for cervical cancer has been used worldwide since the early 20th century. Historically, it was a purely clinical staging system - based on physical examination, cystoscopy, and basic radiology - designed so that even resource-limited countries without advanced imaging could stage patients.
In 2018, FIGO published a landmark revision (Bhatla N, Berek JS et al., Int J Gynecol Obstet 2019;145:129-135), which for the first time incorporated imaging and pathological findings into the staging system.
Berek & Novak: "The FIGO staging system was updated in 2018 to include imaging and pathologic findings... The FIGO staging system is applicable to all histologic types of cervical cancer."
Incidence by stage at diagnosis (Berek & Novak):
- Stage I: 38%
- Stage II: 32%
- Stage III: 26%
- Stage IV: 4%
KEY PRINCIPLE: WHEN IN DOUBT
Berek & Novak: "When there is doubt concerning the stage to which a cancer should be allocated, the earlier stage should be selected."
Once a stage is assigned and treatment initiated, the stage must NOT be changed because of subsequent findings (upstaging would produce erroneous perception of improvement in low-stage disease results).
SIDE-BY-SIDE: OLD (2008) vs. NEW (2018) FIGO STAGING
╔════════════════════════════════════════════════════════════════════════════════╗
║ FIGO CERVICAL CANCER STAGING: 2008 vs 2018 COMPARISON ║
╠══════════╦══════════════════════════════════╦═══════════════════════════════════╣
║ STAGE ║ OLD 2008/2009 ║ NEW 2018 ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IA ║ Microscopic; depth ≤5mm ║ Microscopic; depth <5mm ║
║ ║ AND lateral extent ≤7mm ║ Lateral extent NO LONGER ║
║ ║ ║ considered ← KEY CHANGE ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IA1 ║ Invasion ≤3mm depth ║ Invasion <3mm depth ║
║ ║ AND extension ≤7mm ║ (no lateral limit) ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IA2 ║ Invasion >3mm to ≤5mm ║ Invasion ≥3mm and <5mm ║
║ ║ AND extension ≤7mm ║ (no lateral limit) ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IB ║ Clinically visible lesion OR ║ Deepest invasion ≥5mm ║
║ ║ preclinical >Stage IA ║ confined to cervix uteri ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IB1 ║ Clinically visible lesion ║ Invasion ≥5mm AND <2cm ║
║ ║ ≤4cm ║ ← NEW CUT-OFF (was 4cm) ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IB2 ║ Clinically visible lesion ║ ≥2cm AND <4cm ← NEW STAGE ║
║ ║ >4cm ║ ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IB3 ║ DID NOT EXIST ║ ≥4cm ← BRAND NEW SUBSTAGE ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IIA1 ║ Clinically visible ≤4cm ║ No parametrial; upper 2/3 ║
║ ║ No parametrial ║ vagina; <4cm (unchanged) ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IIA2 ║ Clinically visible >4cm ║ No parametrial; ≥4cm (unchanged) ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IIB ║ Obvious parametrial invasion ║ Parametrial involvement (not ║
║ ║ ║ to pelvic wall) - unchanged ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IIIA ║ Lower 1/3 vagina ║ Lower 1/3 vagina - unchanged ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IIIB ║ Pelvic wall ± hydronephrosis ║ Pelvic wall ± hydronephrosis ║
║ ║ ║ (unless another cause) - same ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IIIC ║ DID NOT EXIST ║ Pelvic/para-aortic LN ║
║ ║ ║ involvement irrespective of ║
║ ║ ║ tumor size ← MAJOR NEW STAGE ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IIIC1 ║ DID NOT EXIST ║ Pelvic LN metastasis only ║
║ ║ ║ + "r" or "p" notation ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IIIC2 ║ DID NOT EXIST ║ Para-aortic LN metastasis ║
║ ║ ║ + "r" or "p" notation ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IVA ║ Adjacent pelvic organs ║ Adjacent pelvic organs ║
║ ║ (bladder/rectum) ║ (bladder/rectum) - unchanged ║
╠══════════╬══════════════════════════════════╬═══════════════════════════════════╣
║ IVB ║ Distant metastasis ║ Distant metastasis - unchanged ║
╚══════════╩══════════════════════════════════╩═══════════════════════════════════╝
COMPLETE FIGO 2018 STAGING TABLE (Berek & Novak, Table 38-1)
┌─────────────────────────────────────────────────────────────────────────┐
│ FIGO 2018 STAGING - CARCINOMA OF CERVIX UTERI │
│ Source: Bhatla N, Berek JS et al., Int J Gynecol Obstet 2019 │
├────────┬────────────────────────────────────────────────────────────────┤
│ STAGE │ DESCRIPTION │
├────────┼────────────────────────────────────────────────────────────────┤
│ I │ Carcinoma strictly confined to the cervix │
│ │ (extension to uterine corpus: DISREGARDED) │
├────────┼────────────────────────────────────────────────────────────────┤
│ IA │ Invasive carcinoma diagnosed ONLY by microscopy │
│ │ Maximum depth of invasion <5mm │
├────────┼────────────────────────────────────────────────────────────────┤
│ IA1 │ Stromal invasion <3mm in depth │
├────────┼────────────────────────────────────────────────────────────────┤
│ IA2 │ Stromal invasion ≥3mm and <5mm in depth │
├────────┼────────────────────────────────────────────────────────────────┤
│ IB │ Invasive carcinoma with deepest invasion ≥5mm │
│ │ Lesion LIMITED to the cervix uteri │
├────────┼────────────────────────────────────────────────────────────────┤
│ IB1 │ Invasion ≥5mm depth AND <2cm in greatest dimension │
├────────┼────────────────────────────────────────────────────────────────┤
│ IB2 │ ≥2cm AND <4cm in greatest dimension │
├────────┼────────────────────────────────────────────────────────────────┤
│ IB3 │ ≥4cm in greatest dimension ★ NEW STAGE │
├────────┼────────────────────────────────────────────────────────────────┤
│ II │ Invades BEYOND UTERUS; NOT to lower 1/3 vagina or pelvic wall │
├────────┼────────────────────────────────────────────────────────────────┤
│ IIA │ Upper 2/3 vagina involved; NO parametrial invasion │
├────────┼────────────────────────────────────────────────────────────────┤
│ IIA1 │ <4cm in greatest dimension │
├────────┼────────────────────────────────────────────────────────────────┤
│ IIA2 │ ≥4cm in greatest dimension │
├────────┼────────────────────────────────────────────────────────────────┤
│ IIB │ Parametrial involvement; NOT to pelvic wall │
├────────┼────────────────────────────────────────────────────────────────┤
│ III │ Lower 1/3 vagina AND/OR pelvic wall AND/OR hydronephrosis │
│ │ AND/OR pelvic/para-aortic lymph nodes ★ LN ADDED │
├────────┼────────────────────────────────────────────────────────────────┤
│ IIIA │ Lower 1/3 vagina; NO pelvic wall extension │
├────────┼────────────────────────────────────────────────────────────────┤
│ IIIB │ Pelvic wall extension AND/OR hydronephrosis / non-functioning │
│ │ kidney (unless due to another cause) │
├────────┼────────────────────────────────────────────────────────────────┤
│ IIIC │ Pelvic AND/OR para-aortic LN involvement ★ ENTIRELY NEW │
│ │ Irrespective of tumor size and extent │
│ │ Uses "r" (imaging) or "p" (pathology) notation │
├────────┼────────────────────────────────────────────────────────────────┤
│ IIIC1 │ Pelvic LN metastasis ONLY │
│ │ → Notation: IIIC1r (imaging) or IIIC1p (pathology) │
├────────┼────────────────────────────────────────────────────────────────┤
│ IIIC2 │ Para-aortic LN metastasis │
│ │ → Notation: IIIC2r (imaging) or IIIC2p (pathology) │
├────────┼────────────────────────────────────────────────────────────────┤
│ IV │ Beyond true pelvis OR biopsy-proven bladder/rectal mucosa │
│ │ (Bullous edema alone = NOT Stage IV) │
├────────┼────────────────────────────────────────────────────────────────┤
│ IVA │ Spread to adjacent pelvic organs (bladder, rectum) │
├────────┼────────────────────────────────────────────────────────────────┤
│ IVB │ Spread to distant organs (liver, lung, bone, etc.) │
└────────┴────────────────────────────────────────────────────────────────┘
DIAGRAM: ANATOMICAL EXTENT BY STAGE
╔══════════════════════════════════════════════════════════════════╗
║ ANATOMICAL PROGRESSION OF CERVICAL CANCER STAGES ║
╠══════════════════════════════════════════════════════════════════╣
║ ║
║ STAGE I ┌─────────────────────────────────────────────┐ ║
║ Confined │ UTERUS │ ║
║ to cervix │ ╔══════╗ │ ║
║ │ ║CERVIX║ ← ALL of Stage I here │ ║
║ └──────────────╚══════╝─────────────────────── ┘ ║
║ ║
║ STAGE IIA Extends to upper 2/3 vagina ║
║ STAGE IIB Parametrium involved (NOT pelvic wall) ║
║ ║
║ STAGE IIIA Lower 1/3 vagina ║
║ STAGE IIIB Pelvic wall / hydronephrosis ║
║ STAGE IIIC Lymph nodes (pelvic → para-aortic) ★ NEW ║
║ ║
║ STAGE IVA Bladder / rectal mucosa ║
║ STAGE IVB Distant organs (lung, liver, bone) ║
╚══════════════════════════════════════════════════════════════════╝
THE FOUR MAJOR CHANGES IN 2018 (EXAM FOCUS)
╔══════════════════════════════════════════════════════════════════════╗
║ FOUR KEY CHANGES: FIGO 2009 → FIGO 2018 ║
╠══════╦═══════════════════════════════════════════════════════════════╣
║ #1 ║ IMAGING AND PATHOLOGY NOW ALLOWED ║
╠══════╬═══════════════════════════════════════════════════════════════╣
║ ║ OLD: Purely clinical staging (bimanual exam, cystoscopy) ║
║ ║ NEW: MRI, CT, PET-CT, pathological findings can be ║
║ ║ used to supplement clinical findings ║
║ ║ → "Pathological findings SUPERSEDE imaging and clinical ║
║ ║ findings" ║
║ ║ → Allows notation: (r) = imaging, (p) = pathology ║
╠══════╬═══════════════════════════════════════════════════════════════╣
║ #2 ║ LATERAL EXTENT REMOVED FROM STAGE IA DEFINITION ║
╠══════╬═══════════════════════════════════════════════════════════════╣
║ ║ OLD IA1: invasion ≤3mm AND extension ≤7mm ║
║ ║ NEW IA1: invasion <3mm ONLY (horizontal extent ignored) ║
║ ║ OLD IA2: invasion >3mm to ≤5mm AND extension ≤7mm ║
║ ║ NEW IA2: invasion ≥3mm and <5mm ONLY ║
║ ║ REASON: Lateral extent had no proven prognostic impact ║
╠══════╬═══════════════════════════════════════════════════════════════╣
║ #3 ║ STAGE IB SPLIT INTO THREE SUBSTAGES (not two) ║
╠══════╬═══════════════════════════════════════════════════════════════╣
║ ║ OLD: IB1 (≤4cm) and IB2 (>4cm) ║
║ ║ NEW: IB1 (<2cm) / IB2 (2-4cm) / IB3 (≥4cm) ║
║ ║ ║
║ ║ WHY? (Berek & Novak): "Stage IB1 denotes lesions <2cm, ║
║ ║ reflecting advances in fertility-sparing procedures that ║
║ ║ are now recommended for selected patients with these ║
║ ║ smaller tumors." ║
║ ║ ║
║ ║ Survival data (FIGO 2018 schema): ║
║ ║ IB1: 91.6% → IB2: 83.3% → IB3: 76.1% (5-yr OS) ║
╠══════╬═══════════════════════════════════════════════════════════════╣
║ #4 ║ STAGE IIIC ADDED FOR LYMPH NODE METASTASIS ║
╠══════╬═══════════════════════════════════════════════════════════════╣
║ ║ OLD: Lymph node metastasis had NO STAGE ║
║ ║ (nodes positive → still staged by tumor extent alone) ║
║ ║ NEW: Pelvic/para-aortic LN metastasis = Stage IIIC ║
║ ║ REGARDLESS of primary tumor size ║
║ ║ ║
║ ║ IIIC1 = Pelvic LN only ║
║ ║ IIIC2 = Para-aortic LN ║
║ ║ ║
║ ║ WHY? (Berek & Novak): "Due to the worsening of outcomes ║
║ ║ when lymph node metastasis is present." ║
║ ║ ║
║ ║ Survival: IIIC1: 75-79% OS / IIIC2: 29-45% OS ║
╚══════╩═══════════════════════════════════════════════════════════════╝
STAGE IIIC NOTATION SYSTEM (New in 2018 - Very Important)
┌──────────────────────────────────────────────────────────────────┐
│ STAGE IIIC - HOW TO WRITE THE NOTATION │
│ (Berek & Novak footnote c, Table 38-1) │
├──────────────────────────────────────────────────────────────────┤
│ │
│ "r" = found by IMAGING (CT/MRI/PET-CT) │
│ "p" = found by PATHOLOGY (surgical specimen / biopsy) │
│ │
│ EXAMPLE 1: │
│ Patient with IB3 tumor, PET-CT shows pelvic node metastasis │
│ → Stage IIIC1r │
│ │
│ EXAMPLE 2: │
│ Patient undergoes radical hysterectomy + PLND, │
│ histology confirms pelvic node metastasis │
│ → Stage IIIC1p │
│ │
│ EXAMPLE 3: │
│ Para-aortic LN confirmed on pathology │
│ → Stage IIIC2p │
│ │
│ RULE: "The type of imaging modality or pathology technique │
│ used should ALWAYS be documented." │
│ │
│ NOTE: LVSI does NOT change the FIGO stage (B&N footnote b) │
└──────────────────────────────────────────────────────────────────┘
IMAGING MODALITIES FOR STAGING (Berek & Novak)
┌──────────────────────────────────────────────────────────────────────┐
│ IMAGING MODALITIES IN 2018 FIGO STAGING │
├────────────────┬─────────────────────────────────────────────────────┤
│ MODALITY │ PERFORMANCE │
├────────────────┼─────────────────────────────────────────────────────┤
│ Clinical exam │ Simple; no cost; foundation of all staging │
│ (EUA) │ Inaccurate for LN and parametrial assessment │
├────────────────┼─────────────────────────────────────────────────────┤
│ CT scan │ Sensitivity 34%, Specificity 97% (para-aortic LN) │
│ │ Accuracy 80-85% │
│ │ False-negative 10-15%, False-positive 20-25% │
├────────────────┼─────────────────────────────────────────────────────┤
│ MRI │ Best for parametrial disease (T2-weighted) │
│ │ More sensitive than CT; equivalent specificity │
│ │ BEST MODALITY for local tumor extent │
├────────────────┼─────────────────────────────────────────────────────┤
│ Ultrasound │ Sensitivity 19%, Specificity 99% │
│ │ False-negative rate 30% → limited use │
├────────────────┼─────────────────────────────────────────────────────┤
│ Lymphangio- │ False-positive 20-40%; False-negative 10-20% │
│ graphy │ Sensitivity 79%, Specificity 73% - largely │
│ │ replaced by PET-CT │
├────────────────┼─────────────────────────────────────────────────────┤
│ PET-CT │ BEST for extrapelvic/distant metastasis detection │
│ │ Better sensitivity + specificity vs CT alone │
│ │ Meta-analysis (72 studies): sensitivity 75% │
│ │ Increasingly standard of care for staging IIIC │
└────────────────┴─────────────────────────────────────────────────────┘
FLOWCHART: HOW TO STAGE IN 2018
╔══════════════════════════════════════════════════════════════════════╗
║ HOW TO ASSIGN FIGO 2018 STAGE - DECISION FLOWCHART ║
╠══════════════════════════════════════════════════════════════════════╣
║ ║
║ STEP 1: CLINICAL EXAMINATION ║
║ (Bimanual + speculum + EUA) ║
║ │ ║
║ ↓ ║
║ STEP 2: IMAGING (when available) ║
║ MRI pelvis → best for local extent ║
║ CT/PET-CT → best for lymph node / distant metastasis ║
║ │ ║
║ ↓ ║
║ STEP 3: PATHOLOGY (when available) ║
║ Biopsy / surgical specimen / sentinel LN / PLND ║
║ → Pathological findings SUPERSEDE imaging + clinical ║
║ │ ║
║ ↓ ║
║ STEP 4: ASSIGN STAGE ║
║ ║
║ Tumor confined to cervix? ║
║ → YES: Stage I (size determines IA1/IA2/IB1/IB2/IB3) ║
║ → NO: Does it extend to vagina? ║
║ → Upper 2/3 vagina only: Stage IIA (size: IIA1/IIA2) ║
║ → Parametrium (not pelvic wall): Stage IIB ║
║ → Lower 1/3 vagina: Stage IIIA ║
║ → Pelvic wall / hydronephrosis: Stage IIIB ║
║ → Lymph nodes (pelvic): Stage IIIC1 (r or p) ║
║ → Lymph nodes (para-aortic): Stage IIIC2 (r or p) ║
║ → Bladder/rectum (biopsy proven): Stage IVA ║
║ → Distant organs: Stage IVB ║
║ ║
║ STEP 5: ADD NOTATION FOR IIIC ║
║ r = imaging confirmed / p = pathology confirmed ║
║ │ ║
║ ↓ ║
║ STEP 6: ONCE ASSIGNED - DO NOT CHANGE ║
║ (Even if later findings suggest higher stage) ║
╚══════════════════════════════════════════════════════════════════════╝
IMPACT OF LYMPH NODE INCLUSION ON CLINICAL PRACTICE
┌──────────────────────────────────────────────────────────────────────┐
│ CLINICAL IMPACT OF NEW STAGE IIIC │
├──────────────────────────────────────────────────────────────────────┤
│ │
│ BEFORE 2018: A patient with Stage IB1 tumor + positive pelvic │
│ nodes was STILL called "Stage IB1" even though nodes were +ve │
│ → Underestimated prognosis │
│ → Caused confusion in international comparisons │
│ │
│ AFTER 2018: Same patient → Stage IIIC1 (r or p) │
│ → Accurate prognostic information │
│ → Directs treatment toward chemoradiation │
│ → Allows meaningful international data comparison │
│ │
│ STAGE SHIFT DATA (published studies): │
│ ~28-35% of patients previously staged IB/IIA were │
│ UPSTAGED to IIIC after applying FIGO 2018 criteria │
│ (Ayhan et al.: 35.3% shifted to IIIC; Yan et al.: 28.2%) │
└──────────────────────────────────────────────────────────────────────┘
FIVE-YEAR SURVIVAL BY STAGE
┌──────────────────────────────────────────────────────────────────┐
│ 5-YEAR OVERALL SURVIVAL BY FIGO 2018 STAGE │
├────────────────┬─────────────────────────────────────────────────┤
│ Stage │ 5-year Survival │
├────────────────┼─────────────────────────────────────────────────┤
│ IA │ ~98-100% │
│ IB1 (<2cm) │ 91.6% │
│ IB2 (2-4cm) │ 83.3% │
│ IB3 (≥4cm) │ 76.1% │
│ IIA │ ~74-80% │
│ IIB │ ~63-67% │
│ IIIA │ ~40-79% │
│ IIIB │ ~38-70% │
│ IIIC1 │ ~66-79% │
│ IIIC2 │ ~30-45% │
│ IVA │ ~15-30% │
│ IVB │ ~5-15% │
└────────────────┴─────────────────────────────────────────────────┘
Note: IIIC1 has BETTER survival than IIIB in many series,
showing lymph node status and tumor extent must be viewed together
SUMMARY: WHAT CHANGED vs. WHAT STAYED THE SAME
┌────────────────────────────────────────────────────────────────────┐
│ QUICK REVISION GRID │
├──────────────────────────────┬─────────────────────────────────────┤
│ WHAT IS NEW IN 2018 │ WHAT REMAINS UNCHANGED │
├──────────────────────────────┼─────────────────────────────────────┤
│ • Imaging (MRI/CT/PET) can │ • Stage I = confined to cervix │
│ be used to assign stage │ • Stage II = beyond cervix, not │
│ │ pelvic wall │
│ • Pathology supersedes │ • IIA1/IIA2 (upper vagina) │
│ imaging + clinical │ • IIB (parametrium) │
│ │ │
│ • Lateral extent (7mm) │ • IIIA (lower 1/3 vagina) │
│ REMOVED from IA definition │ • IIIB (pelvic wall / hydro) │
│ │ │
│ • IB now has 3 substages: │ • IVA (bladder/rectum) │
│ IB1 (<2cm) │ • IVB (distant) │
│ IB2 (2-4cm) ← NEW │ │
│ IB3 (≥4cm) ← ENTIRELY NEW │ • "When in doubt - lower stage" │
│ │ • Stage not changed after treatment │
│ • Stage IIIC ADDED │ starts │
│ IIIC1 (pelvic LN) │ │
│ IIIC2 (para-aortic LN) │ • Applicable to all histologic │
│ r/p notation system │ types of cervical cancer │
└──────────────────────────────┴─────────────────────────────────────┘
EXAM MEMORY AID
"The 4 Big Changes in FIGO 2018" = LINS
┌──────────────────────────────────────────────────────────┐
│ L - Lateral extent REMOVED from Stage IA │
│ I - Imaging (MRI/CT/PET) now ALLOWED for staging │
│ N - New Stage IIIC for lymph Node metastasis │
│ (IIIC1 = pelvic; IIIC2 = para-aortic) │
│ S - Stage IB Split into 3 (IB1/IB2/IB3 at 2cm/4cm) │
└──────────────────────────────────────────────────────────┘
r notation = radiology (imaging)
p notation = pathology confirmed
10-MARK ANSWER STRUCTURE
Para 1 - Introduction + historical context (1 mark): FIGO staging since early 20th century; purely clinical until 2018; landmark revision by Bhatla, Berek et al., IJGO 2019; incidence by stage.
Para 2 - Four major changes with table (3 marks): (1) Imaging/pathology allowed; (2) lateral extent removed from IA; (3) IB split into 3 substages; (4) Stage IIIC added. Full comparison table 2009 vs 2018.
Para 3 - Complete 2018 staging table (2 marks): All stages IA to IVB with descriptions; footnotes a, b, c from Berek & Novak.
Para 4 - Stage IIIC and r/p notation (2 marks): Explanation of IIIC1/IIIC2; r vs p notation system; examples; clinical impact on 28-35% stage upshift.
Para 5 - Imaging modalities + survival data (1 mark): MRI best for local extent; PET-CT best for nodes; survival statistics by substage; survival 91.6% (IB1) down to 30-45% (IIIC2).
Para 6 - Key rules + memory aid (1 mark): When in doubt - lower stage; stage not changed after treatment; LVSI does not change stage; applicable to all histologic types.
Sources: Berek & Novak's Gynecology (16th Ed.), Chapter 38, Tables 38-1 and 38-2, pp. 2223-2228 | Bhatla N, Berek JS et al., FIGO Committee Report, Int J Gynecol Obstet 2019
Enumerate the causes of male infertility and discuss the management of azoospermia berek and novak 10 mark answer with flow charts diagram with easy explanation for m.s main exam
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.